Renew Bioscience

Renew Bioscience is a commercial-stage medical device company dedicated to the clinical advancement and distribution of technologies related to improving cardiovascular, neurological, and overall anatomical function and health outcomes. By focusing on the fundamental principles of enhancing cardiovascular function and circulation efficiency, Renew is revolutionizing the way patients and clinicians prevent and treat some of the most harmful diseases faced today. The company's medical device, named Cerezen, has been granted Breakthrough Device Designation by the U.S. FDA for the treatment of mild cognitive impairment (MCI) and mild Alzheimer's-type dementia caused by Alzheimer's disease. Currently, Renew ECP therapy has been approved for patients with chronic stable angina, as well as for the following uses in healthy individuals: improving vasodilation, increasing VO2, and enhancing blood flow.